Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)

BACKGROUND: MB02 (bevacizumab biosimilar) showed similar structural, functional, and pharmacokinetic properties to reference bevacizumab (Avastin(®); EU-bevacizumab). OBJECTIVES: To confirm clinical similarity between MB02 and EU-bevacizumab, a comparability study was undertaken in the first-line tr...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:BioDrugs
Main Authors: Trukhin, Dmytro, Poddubskaya, Elena, Andric, Zoran, Makharadze, Tamta, Bellala, Ravi Shankar, Charoentum, Chaiyut, Yañez Ruiz, Eduardo P., Fulop, Andrea, Hyder Ali, Irfhan Ali, Syrigos, Kostas, Katgi, Nuran, Lopez Chuken, Yamil Alonso, Rumyana, Ilieva, Reyes-Igama, Jasmin, Costamilan, Rita de Cassia, Del Campo García, Ana, Florez, Amalia, Paravisini, Alexandra, Millan, Susana
פורמט: Artigo
שפה:Inglês
יצא לאור: Springer International Publishing 2021
נושאים:
Original Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8295170/
https://ncbi.nlm.nih.gov/pubmed/33914256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-021-00483-w
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים